R
Renal Ventures Management
Provider of dialysis services for patients
About Renal Ventures Management
Established in 1997, Renal Ventures Management carved a niche in the U.S. healthcare sector as a provider of dialysis services for patients with end-stage renal disease. The company's business model was centered on forming co-venture partnerships with local nephrologists, a strategy that allowed physicians to maintain autonomy over patient care while benefiting from centralized administrative support. This support structure included services such as billing, collections, purchasing, and operational systems, enabling partner physicians to compete more effectively in their local markets.
Renal Ventures operated by building and managing new dialysis centers, as well as selectively acquiring existing ones. The company's management services arm, RenalServ, was responsible for providing and managing highly trained staff for these clinics. A significant milestone occurred in 2011 when the company secured a $30 million capital investment from Goldman Sachs to fuel growth initiatives, including center acquisitions and the expansion of related services. By that time, the company, led by co-founder and VP of strategic services Ellen Davis and CEO Larry Chatfield, operated 25 dialysis centers across six states.
The company's trajectory culminated in its acquisition by DaVita, a leading kidney care provider, in a deal first announced in August 2015 and finalized on May 1, 2017. The initial acquisition price was reported at $415 million, which was later adjusted to approximately $358 million after excluding Renal Ventures' infusion business. At the time of the acquisition agreement, Renal Ventures operated 36 dialysis clinics. The transaction positioned Renal Ventures, then the seventh-largest dialysis provider in the U.S., within the portfolio of the second-largest provider, DaVita. Due to antitrust concerns from the Federal Trade Commission regarding reduced competition in specific local markets, DaVita was required to divest seven of the acquired clinics as a condition of the deal's approval.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2015 | $415M | $415M | DaVita | — |
| LATE VC✓Equity / VC | Jan 2011 | $30M | $120M | Goldman Sachs | — |
Growth signals
Latest recorded traffic for Renal Ventures Management is 130 monthly website visits. Renal Ventures Management's team declined 0.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Renal Ventures Management in the Lakewood ecosystem
The Renal Ventures Management office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
DaVita
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Renal Ventures Management on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Renal Ventures Management’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









